

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

NCT06573008

Status	RECRUITING
Phase	Phase 3
Sponsor	Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Enrollment	328 participants

Key Eligibility Criteria

Inclusion (25)

- Male or female patients aged ≥12 years at the time of signing the informed consent form.
- Patients with a diagnosis of influenza confirmed by all of the following:
 - Positive throat or nose swab by rapid influenza antigen test (RAT) (where rapid influenza virus nucleic acid test or other rapid molecular diagnostic methods are also acceptable);
 - Fever (axillary temperature ≥37.3) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken;
 - At least one of the following systemic symptoms and respiratory symptoms respectively associated with influenza are present with a severity of moderate or greater:

... and 20 more (see full listing online)

Exclusion (15)

- History of allergic reactions attributed to GP681, Acetaminophen, bromohexine hydrochloride or any of the ingredients of its formulation.
- Known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to chronic diarrhea, inflammatory bowel disease, tuberculosis of the intestines, gastrinoma, short bowel syndrome, postoperative gastrectomy, etc.);
- Screening patients who, in the opinion of the investigator, require hospitalization due to severe influenza virus infection;
- Screening patients who, at the time of screening, are clinically diagnosed with bacterial or other viral infections requiring systemic antibacterial or antiviral treatment;
- Cancer patients who are currently receiving or have received chemotherapy or radiation therapy within the past year (excluding non-melanoma skin cancer and thyroid cancer)

... and 10 more (see full listing online)

Locations (1 total)

The people's Hospital of Chizhou, Chizhou, China